JP2018516969A - Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置 - Google Patents

Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置 Download PDF

Info

Publication number
JP2018516969A
JP2018516969A JP2017564421A JP2017564421A JP2018516969A JP 2018516969 A JP2018516969 A JP 2018516969A JP 2017564421 A JP2017564421 A JP 2017564421A JP 2017564421 A JP2017564421 A JP 2017564421A JP 2018516969 A JP2018516969 A JP 2018516969A
Authority
JP
Japan
Prior art keywords
antibody
cxcr4
antigen
specifically binds
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017564421A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516969A5 (enExample
Inventor
ジョセフィン・エム・カルダレッリ
ウェンディ・エル・クレメンス
グレン・エス・クルーグ
ダニエル・イー・ロペス・デ・メネゼス
チン・パン
ポール・ディ・ポナス
ジャン・ビアレ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2018516969A publication Critical patent/JP2018516969A/ja
Publication of JP2018516969A5 publication Critical patent/JP2018516969A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017564421A 2015-06-12 2016-06-13 Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置 Withdrawn JP2018516969A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562174931P 2015-06-12 2015-06-12
US62/174,931 2015-06-12
PCT/US2016/037207 WO2016201425A1 (en) 2015-06-12 2016-06-13 Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways

Publications (2)

Publication Number Publication Date
JP2018516969A true JP2018516969A (ja) 2018-06-28
JP2018516969A5 JP2018516969A5 (enExample) 2019-07-18

Family

ID=56194616

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017564421A Withdrawn JP2018516969A (ja) 2015-06-12 2016-06-13 Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置

Country Status (9)

Country Link
US (1) US20180179282A1 (enExample)
EP (1) EP3307778A1 (enExample)
JP (1) JP2018516969A (enExample)
CN (1) CN108026173A (enExample)
BR (1) BR112017026189A2 (enExample)
CA (1) CA2989144A1 (enExample)
EA (1) EA201792522A1 (enExample)
MX (1) MX2017015811A (enExample)
WO (1) WO2016201425A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022528030A (ja) * 2019-01-07 2022-06-08 トーマス・ジェファーソン・ユニバーシティ 多機能性融合タンパク質及びその使用

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20080053A2 (hr) * 2005-07-01 2009-08-31 Medarex Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1)
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3389652B1 (en) 2015-12-14 2022-09-28 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
ES2935834T3 (es) 2015-12-22 2023-03-10 X4 Pharmaceuticals Inc Métodos para tratar enfermedad de inmunodeficiencia
EP3405203A4 (en) * 2016-01-22 2019-07-24 X4 Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
CN109153722A (zh) 2016-04-08 2019-01-04 X4 制药有限公司 用于治疗癌症的方法
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
EP3471726A4 (en) 2016-06-21 2019-10-09 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CA3045302A1 (en) * 2016-11-29 2018-06-07 Health Research, Inc. Methods and compositions for cancer therapy
US11547694B2 (en) * 2017-03-23 2023-01-10 The General Hospital Corporation CXCR4/CXCR7 blockade and treatment of human papilloma virus-associated disease
US20190233524A1 (en) * 2017-09-18 2019-08-01 Tcm Biotech International Corp. Therapeutic combination and method for treating cancer
CN113150068B (zh) * 2017-09-20 2023-04-04 尚华医药科技(江西)有限公司 一种肽类化合物、其应用及含其的组合物
CA3080821A1 (en) * 2017-11-07 2019-05-16 X4 Pharmaceuticals, Inc. Cancer biomarkers and methods of use thereof
KR102693317B1 (ko) * 2018-03-13 2024-08-07 푼다시온 파라 라 인베스티가시온 바이오메디카 델 호스피탈 우니베르시타리오 라 파즈 암 면역요법을 위한, 활성화되고 확장된 자연 킬러 세포와 조합된 항-cxcr4 항체
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP3866812A1 (en) * 2018-10-17 2021-08-25 BioLineRx Ltd. Treatment of metastatic pancreatic adenocarcinoma
WO2020135415A1 (zh) * 2018-12-24 2020-07-02 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
KR20210141621A (ko) * 2019-03-22 2021-11-23 스미토모 다이니폰 파마 온콜로지, 인크. Pkm2 조정제를 포함하는 조성물 및 그를 사용한 치료 방법
WO2021183650A1 (en) 2020-03-10 2021-09-16 X4 Pharmaceuticals, Inc. Methods for treating neutropenia
JP7579481B2 (ja) 2022-04-13 2024-11-07 ジェネンテック， インコーポレイテッド モスネツズマブの医薬組成物および使用方法
AU2023253705A1 (en) 2022-04-13 2024-10-17 F. Hoffmann-La Roche Ag Pharmaceutical compositions of therapeutic proteins and methods of use
CN119451993A (zh) * 2022-05-04 2025-02-14 佳努克斯治疗公司 用于靶向cd28和pd-l1的肿瘤激活多特异性抗体及其使用方法
CN115487146B (zh) * 2022-10-28 2023-07-18 宁夏医科大学 一种阻断cxcr4/pd-l1双信号的三药共递送纳米体系及其制备方法和应用
KR20250115414A (ko) * 2022-12-07 2025-07-30 이뮨원코 바이오파마슈티컬즈 (상하이) 인크. 항-cd24 항체 및 pd-1-pd-l1 경로 차단 항체를 사용한 암 조합 치료법
EP4658310A1 (en) * 2023-01-30 2025-12-10 Kymab Limited Antibodies

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
HRP20080053A2 (hr) 2005-07-01 2009-08-31 Medarex Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1)
WO2008018641A1 (en) 2006-08-11 2008-02-14 Ono Pharmaceutical Co., Ltd. Monoclonal antibodies against stromal derived factor-1 (sdf-1)
AU2007320024B2 (en) 2006-10-02 2012-11-08 E. R. Squibb & Sons, L.L.C. Human antibodies that bind CXCR4 and uses thereof
FR2915102B1 (fr) 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
KR20100133012A (ko) 2008-05-14 2010-12-20 일라이 릴리 앤드 캄파니 항-ｃｘｃｒ4 항체
US7892546B2 (en) 2008-05-14 2011-02-22 Eli Lilly And Company Anti-CXCR4 antibodies
EP2662383A1 (en) * 2008-08-25 2013-11-13 Amplimmune, Inc. PD-I antagonists and methods for treating infectious disease
EP2172485A1 (en) 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
CA3120172A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
HUE037159T2 (hu) 2009-11-24 2018-08-28 Medimmune Ltd Targetált kötõdõ ágensek B7-H1 ellen
EP3403672A1 (en) 2011-04-20 2018-11-21 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
EP2734234A4 (en) 2011-07-20 2015-01-28 Medimmune Ltd ANTI-CXCR4 ANTIBODIES AND METHOD OF USE THEREOF
EA026153B1 (ru) 2011-11-09 2017-03-31 Бристол-Майерс Сквибб Компани Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
MX349096B (es) 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
AU2013267161A1 (en) 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
US20150322119A1 (en) 2012-12-03 2015-11-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
RU2675516C2 (ru) 2013-08-02 2018-12-19 Пфайзер Инк. Anti-cxcr4 антитела и конъюгаты антитело-лекарство
JP2016527303A (ja) * 2013-08-05 2016-09-08 ケンブリッジ エンタープライズ リミテッド がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022528030A (ja) * 2019-01-07 2022-06-08 トーマス・ジェファーソン・ユニバーシティ 多機能性融合タンパク質及びその使用
JP7587505B2 (ja) 2019-01-07 2024-11-20 トーマス・ジェファーソン・ユニバーシティ 多機能性融合タンパク質及びその使用
US12497439B2 (en) 2019-01-07 2025-12-16 Thomas Jefferson University Multi-functional fusion proteins and uses thereof

Also Published As

Publication number Publication date
CA2989144A1 (en) 2016-12-15
WO2016201425A1 (en) 2016-12-15
BR112017026189A2 (pt) 2018-08-14
CN108026173A (zh) 2018-05-11
US20180179282A1 (en) 2018-06-28
EP3307778A1 (en) 2018-04-18
EA201792522A1 (ru) 2018-05-31
WO2016201425A9 (en) 2017-01-19
MX2017015811A (es) 2018-04-10

Similar Documents

Publication Publication Date Title
JP2018516969A (ja) Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置
US20250011466A1 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US20220298243A1 (en) Anti-pd-1 antibody in combination with an anti-cd30 antibody in cancer treatment
JP2022068352A (ja) 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体の組合せを用いる肺癌の処置法
CN106573977B (zh) 针对ceacam1的人源化抗体
CN104470949A (zh) 通过破坏pd-1/pd-l1信号传输的免疫治疗
JP2017507155A (ja) 抗ｐｄ−１抗体と他の抗癌剤の組合せを使用する腎癌の処置
US20230279096A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
US20240218066A1 (en) Use of anti-pd-1 antibody in combination with first-line chemotherapy in treatment of advanced non-small cell lung cancer
KR20240038008A (ko) 암 치료 방법 및 조성물
JP2024511977A (ja) 抗ｉｌｔ３抗体によるがんの治療方法

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190612

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190930